胶质瘤MAGE-D4剪接变体ab和c的表达及临床意义  

Expression of MAGE-D4 Alternative Splicing Variant ab and c and Its Clinical Significance in Glioma

作　　者：张庆梅[1,2] 罗鑫 刘畅[3] 闭水清[3] 葛盈盈[1,2] 罗彬[1,2] 谢小薰[1,2] 肖绍文[3] 赵文婧[1,2] 沈宁[4] Zhang Qingmei;Luo Xin;Liu Chang(Department of Histology and Embryology,Guangxi Medical University,Nanning 530021,China;Central Laboratory,School of Pre-Clinical Medicine,Guangxi Medical University,Nanning 530021,China;Department of Neurosurgery,The First Affiliated Hospital of Guangxi Medical University,Nanning 530021,China)

机构地区：[1]广西医科大学组织学与胚胎学教研室,南宁530021 [2]广西医科大学基础医学中心实验室,南宁530021 [3]广西医科大学第一附属医院神经外科,南宁530021 [4]广西壮族自治区人民医院口腔颌面外科,南宁530021

出　　处：《华中科技大学学报（医学版）》2021年第5期603-608,共6页Acta Medicinae Universitatis Scientiae et Technologiae Huazhong

基　　金：国家自然科学基金资助项目(No.81560408,No.81460382);广西自然科学基金资助项目(No.2018GXNSFAA050058);广西区域性高发肿瘤早期防治研究教育部重点实验室和广西重点实验室自主研究课题(No.K2015-TKF03,No.GKE2018-09,No.GK2019-08);广西医科大学基础医学科技创新培育基金项目(No.GXMUBMSTCF-G04,No.GXMUBMSTC-T07)。

摘　　要：目的检测肿瘤相关抗原MAGE-D4剪接变体ab和c在胶质瘤和非肿瘤脑组织中的表达情况,分析其临床意义,探讨MAGE-D4选择性剪接与胶质瘤的相关性。方法采用RT-PCR技术进行检测,首先以Primerpremier5.0和Oligo6.0软件设计和评价引物,对引物进行特异性检测和扩增产物测序验证,然后检测89例不同病理类型胶质瘤组织和24例非肿瘤脑组织中MAGE-D4ab和MAGE-D4c的表达,并结合胶质瘤患者临床病理参数进行统计分析。结果所设计的引物可特异性扩增MAGE-D4ab和MAGE-D4c。所检测的组织中,MAGE-D4ab的表达普遍较MAGE-D4c丰富,其中胶质瘤组织中MAGE-D4ab的表达率明显高于非肿瘤脑组织(P<0.05),而MAGE-D4c的表达率与非肿瘤脑组织比较差异无统计学意义(P>0.05);胶质瘤组织和非肿瘤脑组织中均存在MAGE-D4ab-c和MAGE-D4ab+c两种表达形式,其中胶质瘤中MAGE-D4ab-c的表达率高于非肿瘤脑组织(P<0.05),而MAGE-D4ab+c的表达率则与非肿瘤脑组织差异无统计学意义(P>0.05);此外,MAGE-D4ab、MAGE-D4c、MAGE-D4ab-c和MAGE-D4ab+c的表达率均与性别、年龄、肿瘤直径和WHO分级等胶质瘤临床资料无显著性关联。结论MAGE-D4ab及MAGE-D4ab-c形式在胶质瘤中异常表达,可能与胶质瘤的发生相关。Objective To investigate the expression of MAGE-D4 alternative splicing variant ab and c,analyze its clinical significance in glioma and explore the correlation of MAGE-D4 mRNA alternative splicing and glioma.Methods RT-PCR was performed.Firstly,the primers used in this study were designed by Primer premier 5.0 and evaluated by Oligo 6.0.Furthermore,the primers were verified by primer-specific and sequencing experiments.Secondly,the mRNA expression of MAGE-D4 ab and MAGE-D4 c was detected in 89 glioma samples and 24 non-tumor brain tissues.Finally,the correlation of MAGE-D4 ab and MAGE-D4 c expression with clinicopathological parameters of glioma patients was statistically examined.Results The designed primers could specifically amplify MAGE-D4 ab and MAGE-D4 c.In all the tissues tested,the expression of MAGE-D4 ab was generally more abundant than that of MAGE-D4 c,and MAGE-D4 ab was more frequently expressed in glioma tissues than in non-tumor brain tissues(P<0.05),while no statistical difference of MAGE-D4 c expression was explored between glioma tissues and non-tumor brain tissues(P>0.05).Furthermore,we found two existence forms of MAGE-D4 ab and MAGE-D4 c in glioma tissues and non-tumor brain tissues,one was MAGE-D4 ab-c,and the other was MAGE-D4 ab+c.And the expression rate of MAGE-D4 ab-c in glioma tissues was higher than that of non-tumor brain tissues(P<0.05),while the expression rate of MAGE-D4 ab+c was not statistically different in glioma tissues from that of non-tumor brain tissues(P>0.05).Additionally,expression of MAGE-D4 ab,MAGE-D4 c,MAGE-D4 ab-c and MAGE-D4 ab+c had no significant correlation with glioma clinicopathological parameters such as gender,age,tumor size and WHO grade.Conclusion MAGE-D4 ab and MAGE-D4 ab-c are aberrantly expressed in glioma tissues and may be associated with tumorigenesis.

关 键 词：胶质瘤 MAGE-D4 剪接变体 

分 类 号：R739.41[医药卫生—肿瘤]